Insys Therapeutics, Inc. (NASDAQ:INSY)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a report released on Wednesday. They presently have a $14.00 price objective on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of 78.34% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the stock. BidaskClub raised shares of Insys Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 26th. TheStreet downgraded shares of Insys Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, August 21st. Zacks Investment Research downgraded shares of Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 9th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Insys Therapeutics in a report on Thursday, August 3rd. Finally, Piper Jaffray Companies set a $10.00 price target on shares of Insys Therapeutics and gave the stock a “hold” rating in a report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. Insys Therapeutics presently has an average rating of “Hold” and a consensus target price of $13.25.

Insys Therapeutics (INSY) opened at 7.85 on Wednesday. The stock has a 50 day moving average of $9.17 and a 200 day moving average of $10.97. The firm’s market capitalization is $570.66 million. Insys Therapeutics has a 12 month low of $7.55 and a 12 month high of $15.06.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The firm had revenue of $42.60 million for the quarter, compared to the consensus estimate of $36.90 million. During the same period in the prior year, the firm posted $0.13 earnings per share. The company’s revenue for the quarter was down 38.4% on a year-over-year basis. On average, equities analysts predict that Insys Therapeutics will post ($0.29) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/11/insys-therapeutics-insy-outperform-rating-reaffirmed-at-royal-bank-of-canada.html.

In related news, major shareholder John N. Kapoor Trust Dated Sept bought 17,500 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were acquired at an average cost of $8.93 per share, with a total value of $156,275.00. Following the completion of the purchase, the insider now directly owns 31,982 shares of the company’s stock, valued at approximately $285,599.26. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Saeed Motahari bought 5,500 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average cost of $8.92 per share, for a total transaction of $49,060.00. Following the completion of the purchase, the chief executive officer now directly owns 15,400 shares of the company’s stock, valued at $137,368. The disclosure for this purchase can be found here. Company insiders own 67.90% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in Insys Therapeutics by 0.5% in the second quarter. Wells Fargo & Company MN now owns 27,667 shares of the specialty pharmaceutical company’s stock valued at $350,000 after purchasing an additional 126 shares in the last quarter. Eqis Capital Management Inc. raised its stake in Insys Therapeutics by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 66,121 shares of the specialty pharmaceutical company’s stock valued at $836,000 after purchasing an additional 404 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Insys Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 79,943 shares of the specialty pharmaceutical company’s stock valued at $1,012,000 after purchasing an additional 475 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Insys Therapeutics by 4.5% in the second quarter. The Manufacturers Life Insurance Company now owns 21,576 shares of the specialty pharmaceutical company’s stock valued at $274,000 after purchasing an additional 938 shares in the last quarter. Finally, American International Group Inc. raised its stake in Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after purchasing an additional 953 shares in the last quarter. 25.44% of the stock is currently owned by institutional investors and hedge funds.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.